Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiCeram for prevention of eczema in high-risk infants
ACTRN12613000472774Phase 3Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- May 2013
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of EpiCeram in atopic dermatitis (AD) (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoints: Presence of eczema and Transepidermal water loss. Started May 2013; status: completed.
02
Drugs
EpiCeram
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ACTRN12613000472774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000472774.